VIA
STOK icon

Virtus Investment Advisers’s Stoke Therapeutics STOK Stock Holding History

Virtus Investment Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
8,418
+204
+2% +$6.69K 0.08% 295
2025
Q4 		$261K Sell
8,214
-1,413
-15% -$42.5K 0.07% 309
2025
Q3 		$226K Buy
9,627
+1,672
+21% +$28.6K 0.06% 251
2025
Q2 		$90.3K Sell
7,955
-5,368
-40% -$51K 0.03% 376
2025
Q1 		$88.6K Buy
+13,323
New +$124K 0.02% 437

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Virtus Investment Advisers's STOK Position: Q1 2026 in Review

Virtus Investment Advisers increased its Stoke Therapeutics (STOK) stake by 2.5% in Q1 2026, buying an estimated $6.69K and bringing the position to 8,418 shares worth $274K. The position accounts for 0.08% of the portfolio, ranked #295.

Virtus Investment Advisers first reported a position in STOK in Q1 2025 and has held it in 5 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Virtus Investment Advisers held 8,418 shares of Stoke Therapeutics worth $274K as of Q1 2026.
  • Virtus Investment Advisers bought 204 Stoke Therapeutics shares in Q1 2026, an estimated $6.69K.
  • Stoke Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q1 2026, its #295 holding.
  • Virtus Investment Advisers first reported a position in Stoke Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.